spacer
home > ict > summer 2019 > the patient journey
PUBLICATIONS
International Clinical Trials

The Patient Journey





One of the most notable changes in the pharmaceutical industry over the past 10 years is the market shift towards implementing patient-centric practices, programmes, and initiatives as patients are empowered to become more knowledgeable and involved in their treatment. As a result, many life sciences companies are adapting to revolve around the patient at every step of the product lifecycle. This shift from product centricity to patient centricity is moving at varying rates, but it is generally agreed that better patient centricity results in better business and patient outcomes (1).

‘Patient centricity’ can be thought of as the process of designing a product, service, or solution around the patient. In reference to medical products, patient centricity is often the focus during clinical development, with the safety and outcome of every patient in a clinical trial being paramount. During post-approval, the focus is distributed across payers, healthcare providers, regulators, and other company stakeholders. Building patient centricity into every phase of the drug development process requires a comprehensive approach that draws upon numerous stakeholders within the healthcare ecosystem.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Susan Najjar has over 25 years of industry experience with several years in senior leadership and consulting positions. Prior to joining Sciformix, a Covance company, Susan oversaw global marketing activities for Thermo Fisher Scientific’s informatics division, developing growth strategies and implementing innovative marketing programmes. Prior to Thermo, she was accountable for establishing the Gillette Company’s North American Blades and Razors forecasting and planning, executing software product launches at Sun Microsystems, and consulting senior pharma executive teams at Deloitte & Touche. Susan has an MS in Biochemical Engineering from Tufts University, US, and an MBA from MIT Sloan, US.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement